#begin document (bn/cnn/00/cnn_0031); part 000
bn/cnn/00/cnn_0031   0    0                 A    DT  (TOP(S(NP*             -    -   -   -           *         *        (ARG0*   (0
bn/cnn/00/cnn_0031   0    1           leading   VBG           *           lead  02   -   -           *       (V*)            *    -
bn/cnn/00/cnn_0031   0    2           Chinese    JJ           *             -    -   -   -       (NORP)        *             *    -
bn/cnn/00/cnn_0031   0    3    pharmaceutical    JJ           *             -    -   -   -           *         *             *    -
bn/cnn/00/cnn_0031   0    4           company    NN           *)       company   -   1   -           *    (ARG0*)            *)   0)
bn/cnn/00/cnn_0031   0    5              will    MD        (VP*             -    -   -   -           *         *    (ARGM-MOD*)   -
bn/cnn/00/cnn_0031   0    6       manufacture    VB        (VP*    manufacture  01   1   -           *         *           (V*)   -
bn/cnn/00/cnn_0031   0    7               the    DT     (NP(NP*             -    -   -   -           *         *        (ARG1*   (1
bn/cnn/00/cnn_0031   0    8                Ru   NNP           *             -    -   -   -    (PRODUCT)        *             *    -
bn/cnn/00/cnn_0031   0    9          abortion    NN           *             -    -   -   -           *         *             *    -
bn/cnn/00/cnn_0031   0   10              pill    NN           *)            -    -   -   -           *         *             *)   -
bn/cnn/00/cnn_0031   0   11               for    IN        (PP*             -    -   -   -           *         *        (ARG3*    -
bn/cnn/00/cnn_0031   0   12               the    DT        (NP*             -    -   -   -           *         *             *    -
bn/cnn/00/cnn_0031   0   13              U.S.   NNP           *             -    -   -   -        (GPE)        *             *    -
bn/cnn/00/cnn_0031   0   14            market    NN       *)))))        market   -   1   -           *         *             *)   1)
bn/cnn/00/cnn_0031   0   15                 .     .          *))            -    -   -   -           *         *             *    -

bn/cnn/00/cnn_0031   0    0               The    DT  (TOP(S(NP*          -    -   -   -   (ORG*       (ARG0*      *        (ARG0*    -
bn/cnn/00/cnn_0031   0    1              U.S.   NNP           *          -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0    2              Food   NNP       (NML*          -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0    3               and    CC           *          -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0    4              Drug   NNP           *)         -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0    5    Administration   NNP           *)         -    -   -   -       *)           *)     *             *)   -
bn/cnn/00/cnn_0031   0    6          approved   VBD     (VP(VP*     approve  01   1   -       *          (V*)     *             *    -
bn/cnn/00/cnn_0031   0    7               the    DT        (NP*          -    -   -   -       *       (ARG1*      *             *   (1
bn/cnn/00/cnn_0031   0    8              pill    NN           *)         -    -   -   -       *            *)     *             *    1)
bn/cnn/00/cnn_0031   0    9               two    CD   (ADVP(NP*          -    -   -   -       *   (ARGM-TMP*      *             *    -
bn/cnn/00/cnn_0031   0   10             weeks   NNS           *)         -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0   11               ago    RB          *))         -    -   -   -       *            *)     *             *    -
bn/cnn/00/cnn_0031   0   12                 ,     ,           *          -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0   13               but    CC           *          -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0   14               did   VBD        (VP*          do  01   -   -       *            *    (V*)            *    -
bn/cnn/00/cnn_0031   0   15               not    RB           *          -    -   -   -       *            *      *    (ARGM-NEG*)   -
bn/cnn/00/cnn_0031   0   16          disclose    VB        (VP*    disclose  01   1   -       *            *      *           (V*)   -
bn/cnn/00/cnn_0031   0   17               the    DT     (NP(NP*          -    -   -   -       *            *      *        (ARG1*   (0
bn/cnn/00/cnn_0031   0   18        drugmakers   NNS           *          -    -   -   -       *            *      *             *    -
bn/cnn/00/cnn_0031   0   19                 '   POS           *)         -    -   -   -       *            *      *             *    0)
bn/cnn/00/cnn_0031   0   20          identity    NN        *))))         -    -   -   -       *            *      *             *)   -
bn/cnn/00/cnn_0031   0   21                 .     .          *))         -    -   -   -       *            *      *             *    -

bn/cnn/00/cnn_0031   0    0              The    DT    (TOP(S(NP*             -    -   -   -           *      *      *       (ARG0*    (0
bn/cnn/00/cnn_0031   0    1          Chinese    JJ             *             -    -   -   -       (NORP)     *      *            *     -
bn/cnn/00/cnn_0031   0    2          company    NN             *)       company   -   1   -           *      *      *            *)    0)
bn/cnn/00/cnn_0031   0    3              has   VBZ          (VP*           have  01   -   -           *    (V*)     *            *     -
bn/cnn/00/cnn_0031   0    4             been   VBN          (VP*             be  03   -   -           *      *    (V*)           *     -
bn/cnn/00/cnn_0031   0    5    manufacturing   VBG          (VP*    manufacture  01   1   -           *      *      *          (V*)    -
bn/cnn/00/cnn_0031   0    6               Ru   NNP          (NP*)            -    -   -   -    (PRODUCT)     *      *       (ARG1*)   (1)
bn/cnn/00/cnn_0031   0    7              for    IN          (PP*             -    -   -   -           *      *      *   (ARGM-TMP*     -
bn/cnn/00/cnn_0031   0    8               at    IN  (NP(QP(ADVP*             -    -   -   -           *      *      *            *     -
bn/cnn/00/cnn_0031   0    9            least   JJS             *)            -    -   -   -           *      *      *            *     -
bn/cnn/00/cnn_0031   0   10            seven    CD             *)            -    -   -   -           *      *      *            *     -
bn/cnn/00/cnn_0031   0   11            years   NNS         *)))))            -    -   -   -           *      *      *            *)    -
bn/cnn/00/cnn_0031   0   12                .     .            *))            -    -   -   -           *      *      *            *     -

bn/cnn/00/cnn_0031   0    0          For    IN  (TOP(S(PP*          -    -   -   -   *   (ARGM-PRP*   -
bn/cnn/00/cnn_0031   0    1         more   JJR        (NP*          -    -   -   -   *            *   -
bn/cnn/00/cnn_0031   0    2     business    NN       (NML*    business   -   1   -   *            *   -
bn/cnn/00/cnn_0031   0    3          and    CC           *          -    -   -   -   *            *   -
bn/cnn/00/cnn_0031   0    4     consumer    NN           *)         -    -   -   -   *            *   -
bn/cnn/00/cnn_0031   0    5         news    NN          *))       news   -   1   -   *            *)  -
bn/cnn/00/cnn_0031   0    6            ,     ,           *          -    -   -   -   *            *   -
bn/cnn/00/cnn_0031   0    7        click    VB           *       click  01   1   -   *          (V*)  -
bn/cnn/00/cnn_0031   0    8           on    IN        (PP*          -    -   -   -   *   (ARGM-LOC*   -
bn/cnn/00/cnn_0031   0    9           to    IN        (PP*          -    -   -   -   *            *   -
bn/cnn/00/cnn_0031   0   10    cnnfn.com   ADD      (NP*)))         -    -   -   -   *            *)  -
bn/cnn/00/cnn_0031   0   11            .     .          *))         -    -   -   -   *            *   -

#end document
